Skip to content

Use of saliva for screening patients with COVID-19

Identification of biomarkers in the saliva of patients with COVID-19 for use in screening: a clinical-laboratory study based on artificial intelligence

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
REBEC
Registry ID
RBR-5sw6sjz
Enrollment
Unknown
Registered
2021-07-07
Start date
2020-10-01
Completion date
Unknown
Last updated
2025-10-27

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Coronavirus Infections

Interventions

Control group: saliva, blood and naso / oropharynx (swab) samples will be collected from 66 participants at different times after the onset of symptoms: T0 (3 to 8 days)
T1 (10 to 15 days) and T2 (17 to 22 days). Saliva will be collected at times T0, T1 and T2, blood at times T0 and T2 and the swab at times T0 and T2. A sample of unstimulated saliva will be collected
T1 (10 to 15 days) and T2 (17 to 22 days). Saliva will be collected at times T0, T1 and T2, blood at times T0 and T2 and the swab at times T1 and T2. A sample of unstimulated saliva will be collected
G07.203.650.250.800
E06.761.726.794
E01.370.225.998.110

Sponsors

Instituto Federal do Paraná
Lead Sponsor
Instituto Federal do Paraná
Collaborator

Eligibility

Age
20 Years to 45 Years

Inclusion criteria

Inclusion criteria: Case group: adult adults; 20 to 45 years; the city of Londrina; without comorbidities; non-smoking; of both sexes; with symptoms for CODIV-19; assisted at the Sabará-Londrina Emergency Care Unit. Control group: adult adults; 20 to 45 years; the city of Londrina; without comorbidities; non-smoking; of both sexes; no symptoms for CODIV-19.

Exclusion criteria

Exclusion criteria: Case group: volunteers who present comorbidities during the execution of the research; who start to use medication for continuous use that interferes with the quantity and quality of saliva; who in the course of the research are hospitalized for the treatment of the disease or give up participating in the research. Control group: volunteers who present comorbidities during the execution of the research; who start to use medications for continuous use that interfere in the quantity and quality of saliva; and that in the course of the research they are tested positive for COVID-19 or who quit participating of the research.

Design outcomes

Primary

MeasureTime frame
Improvement in the screening capacity of COVID-19, assessed by the identification of at least one saliva chemical or protein biomarker.

Secondary

MeasureTime frame
Reduction of SARS-CoV-2 viral load, assessed by polymerase chain reaction, by 50% after 30 minutes of tooth brushing.

Countries

Brazil

Contacts

Public ContactMarcelo Poleti
marcelo_poleti@yahoo.com.br+55 43 3354-1500

Outcome results

None listed

Source: REBEC (via WHO ICTRP)